Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease.
Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease.
复制标题
DOI：
10.1136/fg.2010.001362
复制
发表时间：
2011-01
影响因子：
2.6
通讯作者：
Mansfield JC
中科院分区：
文献类型：
--
作者：
Lamb CA;Mansfield JC
克罗恩病和溃疡性结肠炎是慢性复发性胃肠道疾病，其特征在于炎症细胞流入受影响的肠粘膜。在临床实践和研究中，诊断和重新评估这些疾病的主要方法是通过侵入性血清学、放射学、内窥镜和组织学评估。在临床试验中，疾病活动性通常使用上述测试加上临床指数（如克罗恩病活动指数和溃疡性结肠炎活动指数）的组合进行评估。这些工具依赖于对症状的主观评估，因此通常与粘膜炎症或粘膜愈合无关，而粘膜炎症或粘膜愈合可能是长期炎症性肠病（IBD）管理的首选治疗终点。粪便生物标志物钙卫蛋白和乳铁蛋白是中性粒细胞衍生的蛋白质，其在粪便中稳定，并且可以通过定量ELISA在少量粪便样品中检测到。两者的浓度在胃肠道粘膜炎症患者中升高。它们提供了一种独特的、廉价的、非侵入性的检测活动性炎症疾病的方法。它们可用于筛选IBD，并作为粘膜愈合的替代标志物，它们可用于监测对治疗干预或手术的反应。它们还可以预测疾病的临床过程。本临床综述旨在讨论这些生物标志物在IBD中的现有证据，局限性和潜在的未来用途。
Crohn's disease and ulcerative colitis are chronic relapsing gastrointestinal conditions characterised by an influx of inflammatory cells to the affected gut mucosa. The mainstay of diagnosing and re-evaluating these conditions in clinical practice and research is by invasive serological, radiological, endoscopic and histological assessment. In clinical trials, disease activity is often evaluated using a combination of the above tests plus clinical indices such as the Crohn's Disease Activity Index and Ulcerative Colitis Activity Index. These tools rely on subjective assessment of symptoms and so, often, do not correlate with mucosal inflammation or mucosal healing, which may be the preferred therapeutic end point for long-term inflammatory bowel disease (IBD) management. The faecal biomarkers calprotectin and lactoferrin are neutrophil derived proteins that are stable in faeces and can be detected by quantitative ELISA in small stool samples. Concentrations of both are raised in patients with gastrointestinal mucosal inflammation. They provide a unique, inexpensive, non-invasive method of testing for active inflammatory disease. They can be used to screen for IBD and as a surrogate marker of mucosal healing they are useful in monitoring the response to therapeutic intervention or surgery. They may also predict the clinical course of the disease. This clinical review aims to discuss the current evidence, limitations and potential future uses of these biomarkers in IBD.
登录
查看更多内容
影响因子：
12.6
作者：
Jones, Jennifer;Loftus, Edward V., Jr.;Sandborn, William J.
通讯作者：
Sandborn, William J.
影响因子：
29.4
作者：
SAVERYMUTTU, SH;CAMILLERI, M;CHADWICK, VS
通讯作者：
CHADWICK, VS
影响因子：
3.9
作者：
Scarpa, Marco;D'Inca, Renata;Angriman, Imerio
通讯作者：
Angriman, Imerio
影响因子：
29.4
作者：
Parsi, MA;Shen, B;Lashner, BA
通讯作者：
Lashner, BA
影响因子：
4.9
作者：
Schnitzler, Fabian;Fidder, Herma;Rutgeerts, Paul
通讯作者：
Rutgeerts, Paul